IP Licensing for UK Telehealth Platforms

Telehealth founders often sign software or content licences quickly because the commercial pressure feels urgent. That is where expensive problems start. Common mistakes include assuming the platform owns all code created by contractors, accepting a supplier's standard licence without checking data use rights, and treating clinical content as if copyright ownership automatically covers regulatory and brand issues too.

A licensing agreement for telehealth platforms in the UK needs to do more than say who can use a piece of software. It should clearly set out who owns the technology, what the licence actually covers, how patient-facing materials can be used, what happens to improvements, and what rights survive when the deal ends. If you are negotiating with a software developer, white labelling a health app, licensing clinical questionnaires, or sharing APIs with a care provider, these are the points worth sorting out before you sign.

Overview

A licensing agreement telehealth platforms UK businesses sign should match the real commercial model, not just the name of the product. The key question is not whether there is a licence, but whether the licence gives the right party the right rights, for the right use, for long enough, with sensible limits on risk and exit.

• Confirm exactly what intellectual property is being licensed, including software, source code, trade marks, content, databases, APIs, designs and clinical workflows.
• Check whether the licence is exclusive, sole or non-exclusive, and whether sublicensing is needed for group companies, clinicians, contractors or NHS and private partners.
• Set clear rules on modifications, updates, integrations and ownership of new features or improvements.
• Deal expressly with patient data, anonymised datasets, security obligations and permitted data uses, because IP rights and data protection rights are not the same thing.
• Review restrictions on territory, field of use, branding, hosting, service levels, audit rights, termination rights and handover on exit.
• Make sure warranties, indemnities and liability caps reflect the real risk if the platform fails, infringes third party rights or cannot be lawfully used.

What Licensing Agreement Telehealth Platforms Means For UK Businesses

A telehealth licence is the contract that decides who may use technology, content or branding, and on what terms. For UK businesses, that usually means much more than a simple permission to use an app.

Most telehealth platforms combine several separate rights. A single product might include proprietary software, user interface designs, clinician triage questions, educational videos, AI-supported workflows, trade marks, APIs, and reporting dashboards. If the agreement only describes the licensed asset in vague terms such as "the platform", you may not actually have rights to every element your business relies on.

What might be licensed in a telehealth deal?

The licensed assets often sit across different suppliers and contributors. Before you accept the provider's standard terms, identify each category of IP that matters commercially.

• Application software, web portals and mobile app code
• Source code or object code access rights
• Platform branding, logos and white label assets
• Clinical content, questionnaires, templates and patient communications
• Databases, taxonomies, analytics dashboards and reporting formats
• APIs and integration tools for pharmacies, GP systems, payment providers or booking systems
• Training materials, implementation documents and user manuals
• AI tools, prompt libraries and decision-support outputs, where used

This matters because each category may need different permission settings. You may be allowed to use software internally, but not adapt it. You may be allowed to display a supplier's trade mark, but only within branding guidelines. You may receive access to clinical content, but not permission to localise it for your own specialism or patient cohort.

Ownership and licensing are different

A licence gives permission. It does not automatically transfer ownership. This is where founders often get caught, especially when they pay for custom build work and assume payment means the business owns the resulting code.

Under UK law, who owns copyright in software, content or design work depends on who created it, under what arrangement, and what the contract says. If an external developer, agency or clinical consultant creates material and the contract only grants a limited licence back, your company may not control the asset it thought it was buying.

That becomes a real problem before fundraising, before a sale, or before you expand into new channels. Investors and commercial partners usually want to know that the business owns its core IP or at least has a secure enough licence to operate without interruption.

Why telehealth licences need sector-specific drafting

Telehealth products sit close to privacy, patient safety and regulatory expectations. A standard SaaS licence may miss the points that actually matter in a health setting.

For example, a telehealth platform may rely on symptom checker logic, consultation forms, prescribing prompts or clinician messaging pathways. If you cannot modify these features quickly, your service may struggle to respond to clinical governance changes or updated care protocols. If the agreement is silent on improvement rights, each update may become a separate commercial negotiation.

Branding also needs attention. Many UK telehealth businesses operate under white label, co-branded or partner-branded models. A licensing agreement should state who controls the patient-facing name, app store presentation, logo use, and any restrictions on marketing statements. Brand confusion creates risk not just for trade mark rights, but also for customer complaints and trust.

Legal Issues To Check Before You Sign

The main legal issues are scope, control, risk allocation and exit. Before you sign a contract, you want the document to reflect what your platform actually needs to do in practice.

1. Define the licence scope properly

The licence grant clause should answer simple business questions in clear terms. Who can use the platform, for what purpose, in which territories, on which channels, and for how long?

Check whether the agreement covers:

• Use by your company only, or also affiliates and subcontractors
• Use by clinicians, pharmacists, practice staff and other authorised users
• White labelling or resale to partner clinics or employers
• Private healthcare, NHS projects, occupational health or insurer-backed services
• Use in the UK only, or internationally as the business grows
• Temporary pilots versus long-term operational use

If your commercial model includes group companies or delivery partners, you may need an express sublicensing right. Without it, your business could be in breach simply because another entity in the group uses the same system.

2. Deal with customisation, updates and improvements

Telehealth platforms rarely stay static. Product teams request new features, compliance teams need updates, and partners ask for integrations. The agreement should say who can request changes, who pays, who owns the resulting IP and whether those changes become part of the licensed product for everyone.

Founders often focus on ownership of bespoke work, but usage rights matter just as much. Even if the supplier keeps ownership of an improvement, your company may need an irrevocable licence to keep using it after the relationship ends or changes.

Watch for clauses that let the supplier reuse everything you funded without restriction while limiting your own future rights. That may be commercially acceptable, but only if you price and structure the deal with that in mind.

3. Separate IP rights from data rights

IP ownership does not answer data protection questions. A supplier may own software while your business controls patient data, or the position may be split depending on the dataset and the role each party plays.

Before you rely on a verbal promise, make sure the contract deals separately with:

• Who determines the purpose and means of processing personal data
• Whether the supplier acts as a processor, joint controller or independent controller in any context
• Whether de-identified or anonymised data can be reused for analytics, product development or AI training
• How data will be returned, exported or deleted on termination
• Security standards, incident reporting and access controls

In telehealth, this line matters because businesses sometimes grant broad rights to "service data" without realising the drafting may permit secondary uses that customers or clinical partners would object to. Your privacy notice and your licence position need to line up.

4. Check trade mark and branding permissions

If the deal includes white labelling, co-branding or partner distribution, brand rights should be explicit. A software licence does not automatically give a broad right to use a logo or trading name.

Look for practical points such as:

• Who owns the patient-facing brand
• Whether the licensee can use logos in app stores, onboarding flows and marketing materials
• Approval rights for co-branded campaigns
• Rules on domain names, social media handles and marketplace listings, where relevant
• What happens to branding when the agreement ends

This is especially important before you invest in branding, patient materials or partner sales collateral. Rebranding after a dispute is expensive and disruptive.

5. Review IP infringement risk and liability

A good licence should say what happens if a third party claims the telehealth platform infringes its IP rights. You do not want to discover after a complaint arrives that the supplier disclaims all responsibility.

Check for warranties that the supplier has the right to license the product, and review any indemnity for third party IP infringement. Then compare that protection with the liability cap. An indemnity has less practical value if it is heavily narrowed or subject to a low overall cap.

Also consider business continuity. If there is an infringement claim, can the supplier modify the product, obtain replacement rights, or refund fees? If the platform is central to patient bookings or consultations, a simple termination right may not be enough.

6. Plan the exit before the relationship starts

Exit terms are not a minor back-end issue. For telehealth businesses, poor exit drafting can leave you unable to migrate records, preserve service continuity or keep using core workflows during a transition period.

Your agreement should cover:

• Termination triggers, including convenience, breach, insolvency and regulatory concerns
• Notice periods and cure periods
• Access to data exports in usable formats
• Migration support, transition services and charges
• Whether clinicians and admins can still access historic records for a limited period
• What happens to bespoke features, branded assets and integrations after termination

These points matter before you sign because your leverage is highest then. Once the platform is embedded in clinical operations, renegotiating exit support is much harder.

Common Mistakes With Licensing Agreement Telehealth Platforms

The most common mistake is treating the licence as a standard software document when the product is actually part software, part content, part data arrangement and part brand licence. Telehealth contracts need tighter drafting because more things can go wrong at once.

Assuming payment means ownership

Paying for development does not automatically transfer copyright. If the agreement does not assign IP or grant adequate ongoing rights, your business may be paying for a platform it cannot freely adapt, sell or migrate.

This often happens with early MVP builds, clinician-created content libraries and outsourced UX work. The issue usually appears later, when a founder wants a new supplier to take over or wants to raise investment.

Accepting vague definitions of the licensed product

If the schedule does not clearly list what is included, disputes follow. A provider may say analytics modules, patient education videos or API access were never part of the original licence, even if your team assumed they were.

Vagueness is particularly risky where the platform includes third party components. Your supplier may only be passing through limited rights from another vendor, which can affect your ability to scale or modify the service.

Ignoring field-of-use restrictions

Some telehealth licences permit use only for a narrow service line. A symptom checker licensed for employee wellbeing, for example, may not be approved under the contract for general primary care or specialist triage.

If your business model may expand, ask for drafting that permits realistic future use cases or a clear mechanism to add them. Otherwise you may need to renegotiate at the point your business starts gaining traction.

Overlooking contractor and clinician access

Many telehealth businesses rely on a mix of employed staff, freelance clinicians, agencies and outsourced support providers. If the licence only allows use by direct employees, routine operational access may technically breach the contract.

This is an easy point to miss before you sign, especially when procurement teams focus on price and product features rather than user definitions.

Confusing anonymised data rights with free commercial use

Suppliers often ask for broad rights to use de-identified platform data for service improvement or benchmarking. That may be acceptable in principle, but the wording needs care.

Questions worth asking include:

• What exactly counts as anonymised or aggregated data under the contract?
• Who decides when data is sufficiently de-identified?
• Can the supplier combine datasets across customers?
• Can the data be used to train AI models or commercialise new tools?
• Will any outputs compete with your own service?

The issue is not that all reuse is improper. The issue is that broad drafting can quietly shift value away from the telehealth business that generated the dataset.

Leaving service levels outside the core deal

A licence may technically grant use rights while saying little about uptime, support response times or patching obligations. For a telehealth business, that gap can be serious if clinicians and patients depend on the platform every day.

If the provider hosts the system, the legal package may need more than an IP licence. It may also need service levels, support commitments, change control, business continuity measures and security obligations that fit the sensitivity of the service.

Relying on termination without transition support

Founders sometimes feel reassured because the contract contains a termination right. In reality, the key issue is what happens the day after termination.

If there is no handover plan, your business might lose access to integrations, patient communications templates, booking logic or historic reporting formats. A clean exit often matters more than the formal right to leave.

FAQs

Does a telehealth platform licence need to be exclusive?

No. Many telehealth software licences are non-exclusive. Exclusivity may be useful for a specific territory, speciality or distribution channel, but it usually comes with higher cost and tighter performance obligations.

Who owns custom features built for our business?

The contract decides this. A supplier may own the underlying platform and also own bespoke developments, while granting your business a licence to use them. If ownership matters commercially, it should be stated clearly in the drafting.

Can we let partner clinics or freelance clinicians use the platform under our licence?

Only if the agreement allows it. Check the authorised user definition and any sublicensing clause. Do not assume contractors, affiliates or partner organisations are automatically covered.

Do IP clauses also cover patient data rights?

No. IP terms and data protection terms do different jobs. Your agreement should deal separately with software and content rights, and with personal data handling, reuse, security and deletion.

What should happen when the licence ends?

The contract should set out what access stops, what data is returned or deleted, whether transition support is available, and whether any rights survive for historic records, branded assets or bespoke features. These points are best negotiated before you sign.

Key Takeaways

• A licensing agreement telehealth platforms UK businesses sign should clearly identify every asset being licensed, not just refer loosely to "the platform".
• Ownership and permission to use are different, so custom development, clinical content and branding rights need specific drafting.
• Telehealth deals often combine software, data, content and brand issues, which means standard SaaS terms may leave important gaps.
• Before you sign, focus on scope, sublicensing, improvement rights, data use, infringement protection, liability caps and exit support.
• The main risk is accepting broad standard terms that do not match your real operating model, partner structure or regulatory expectations.
• If you are reviewing or negotiating licensing agreement telehealth platforms and want help with licence scope, IP ownership, data use clauses, exit terms, you can reach us on 08081347754 or team@sprintlaw.co.uk for a free, no-obligations chat.